Form 4: Health Catalyst Executive Benjamin Landry Sells Shares Under 10b5-1 Plan

Health Catalyst's General Counsel, Benjamin Landry, sold 2,466 shares of common stock at $7.3891 per share on September 6, 2024, under a pre-arranged trading plan.

Summary

• On September 6, 2024, Benjamin Landry, General Counsel of Health Catalyst, Inc., sold 2,466 shares of common stock.
• The sale was executed at a price of $7.3891 per share.
• This transaction was conducted under a written trading plan adopted on March 1, 2024, in accordance with Rule 10b5-1.
• Following the transaction, Landry directly owns 100,937 shares of Health Catalyst common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan and doesn't necessarily reflect a change in the executive's view of the company's prospects.

Industry Context

Insider sales are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares while avoiding accusations of trading on material non-public information. The market will likely interpret this sale in the context of Health Catalyst's overall performance and future prospects.

Stakeholder Impact

• The sale could have a minor negative impact on shareholder sentiment, although the pre-planned nature of the sale mitigates this concern.

Key Dates